Sept. 29.2020, Shanghai
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN, "Biohaven") announced today that BioShin Limited ("BioShin") its Asia-Pacific Subsidiary, has closed a $60M Series A investment round. The financing was led by OrbiMed, with participation from Cormorant Asset Management LLC, HBM Healthcare Investments Ltd, Surveyor Capital (a Citadel Company), and Suvretta Capital Management, LLC.
The company named Donnie McGrath as BioShin President and Executive Chairman, and Karl Lintel as BioShin Chief Executive Officer. Also appointed Vlad Coric and Donnie McGrath of Biohaven, and David Wang of OrbiMed to Board of Directors.
Currently, BioShin is initiating NURTEC ODT Phase 3 study for acute migraine in China and Korea, and China registrational study of troriluzole in Spinocerebellar Ataxia in 4Q20.